How does A068270's PS Ratio compare to its peers?

A068270 is good value based on its Price-To-Sales Ratio (12.4x) compared to the peer average (16.1x).

How does A068270's PS Ratio compare vs other companies in the KR Biotechs Industry?

A068270 is expensive based on its Price-To-Sales Ratio (12.4x) compared to the KR Biotechs industry average (9.2x).

What is A068270's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A068270 is expensive based on its Price-To-Sales Ratio (12.4x) compared to the estimated Fair Price-To-Sales Ratio (11.3x).

What is the Fair Price of A068270 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A068270 (₩173500) is trading below our estimate of [[fair value]] (₩187577.28)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Celltrion (KOSE:A068270) - Stock Price, News & Analysis

A068270 Stock Overview

Develops and produces drugs based on proteins for the treatment of oncology in South Korea. More details

A068270 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 7.5% below our estimate of its fair value

Earnings are forecast to grow 73.61% per year

Analysts in good agreement that stock price will rise by 41.7%

Risk Analysis

Profit margins (6.5%) are lower than last year (26.2%)

Shareholders have been diluted in the past year

Celltrion, Inc. Competitors

Hugel

KOSDAQ:A145020

₩3.0t

NatureCellLtd

KOSDAQ:A007390

₩1.4t

PharmaResearch

KOSDAQ:A214450

₩2.1t

GC Biopharma

KOSE:A006280

₩1.5t

Price History & Performance

Summary of all time highs, changes and price drops for Celltrion
Historical stock prices
Current Share Price	₩173,500.00
52 Week High	₩241,000.00
52 Week Low	₩157,500.00
Beta	0.15
11 Month Change	-6.57%
3 Month Change	-14.32%
1 Year Change	3.27%
33 Year Change	-14.00%
5 Year Change	13.29%
Change since IPO	1,645.89%

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22

Recent updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Nov 22

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Shareholder Returns

	A068270	KR Biotechs	KR Market
7D	4.9%	-4.5%	2.4%
1Y	3.3%	21.1%	-4.0%

Return vs Industry: A068270 underperformed the KR Biotechs industry which returned 21.1% over the past year.

Return vs Market: A068270 exceeded the KR Market which returned -4% over the past year.

Price Volatility

Is A068270's price volatile compared to industry and market?
A068270 volatility
A068270 Average Weekly Movement	4.3%
Biotechs Industry Average Movement	8.0%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A068270 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A068270's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2002	n/a	Hyong-Gi Kim	www.celltrion.com

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis.

Celltrion, Inc. Fundamentals Summary

How do Celltrion's earnings and revenue compare to its market cap?
A068270 fundamental statistics
Market cap	₩35.77t
Earnings (TTM)	₩187.10b
Revenue (TTM)	₩2.88t

191.2x

P/E Ratio

12.4x

P/S Ratio

Is A068270 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A068270 income statement (TTM)
Revenue	₩2.88t
Cost of Revenue	₩1.60t
Gross Profit	₩1.28t
Other Expenses	₩1.09t
Earnings	₩187.10b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	907.57
Gross Margin	44.47%
Net Profit Margin	6.50%
Debt/Equity Ratio	12.6%

How did A068270 perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

51%

Payout Ratio

A068270 Stock Overview

Rewards

Risk Analysis

Celltrion, Inc. Competitors

KOSDAQ:A145020

₩3.0t

KOSDAQ:A007390

₩1.4t

KOSDAQ:A214450

₩2.1t

KOSE:A006280

₩1.5t

Price History & Performance

Recent News & Updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024

Consensus EPS estimates fall by 16%

Celltrion, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease

Recent updates

Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024

Consensus EPS estimates fall by 16%

Celltrion, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases

Consensus EPS estimates fall by 21%

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like